T-cell vaccine for COVID-19 may last longer t

The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. Focusing on the T-cell instead, Penn State researchers partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an artificial intelligence-generated vaccine in a live viral challenge model. Such a vaccine may provide long-lasting immunity against future emerging variants and could be used as a model for other seasonal viral diseases like the flu.

Related Keywords

Denmark , Bhuvana Katkere , Michael Schantz Klausen , Mckayla Nicol , Girish Kirimanjeswara , Julie Hinchelli Emdrup , Katherine Restori , Sophie Schussek , Anders Bundgaard , Innovation Fund Denmark , College Of Agricultural Sciences , Centers For Disease , Huck Institutes Of Life Sciences , National Institutes Of Health , Evaj Pell Laboratory , Penn State , Evaxion Biotech , Rapidly Adaptive Viral , Gry Persson , Fund Denmark , Huck Institutes , Life Sciences , Agricultural Sciences , National Institutes , Disease Control ,